It's a spinoff: Novartis parts ways with Sandoz just as its generics biz shows signs of recovery

Less than a year into a strategic review, Novartis has decided on a plan for its Sandoz generics unit: a spinoff.

Novartis plans to spin Sandoz into a publicly traded, standalone business, creating Europe’s largest generics company, the Swiss drugmaker said Thursday.